Zhongke Biopharmaceutical

Bohui Biopharmaceutical (formerly Zhongke Biopharmaceutical) is a leading Chinese vaccine manufacturer headquartered in the Yanjiao High-tech Zone, Hebei. Established in 1995, the company focuses on the research, development, and large-scale production of human vaccines, with a portfolio that includes marketed products for rabies, influenza, and meningococcal disease. As a key subsidiary of the publicly traded Beijing Bohui Innovation Biotechnology Group, it benefits from a broad biopharmaceutical platform encompassing diagnostics and blood products. The company's R&D pipeline is actively advancing next-generation candidates, such as trivalent influenza subunit vaccines and pneumococcal vaccines, to address public health needs in China and international markets. Its manufacturing facilities are GMP-certified and designed for high-capacity output to support national immunization programs.